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Fact Sheet for Healthcare Providers:  
Interpreting Zika MAC-ELISA Test Results 
 
Updated: December 6, 2016 
 
Dear Healthcare Provider: 
 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization 
(EUA) to authorize the use of the Centers for Disease Control and Prevention (CDC) Zika IgM 
antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA).  This assay 
provides in vitro qualitative detection of human IgM antibodies to Zika virus.  The Zika MAC-
ELISA is intended for use in serum of individuals meeting CDC Zika clinical and/or 
epidemiological criteria for testing in qualified laboratories designated by the CDC 
(see http://www.cdc.gov/zika/hc-providers/index.html). It can also be used in cerebrospinal 
fluid (CSF) when submitted with a patient-matched serum sample.   This test should be 
performed according to CDC’s algorithm for Zika testing 
(see http://www.cdc.gov/zika/laboratories/lab-guidance.html).  
 
The information in this Fact Sheet is to inform you of the significant known and potential risks 
and benefits of the emergency use of the Zika MAC-ELISA 
(see http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm).  
 
Why is this test needed at this time? 
 
Public health officials have determined that Zika virus poses a potential public health 
emergency. Current information on Zika virus infection for healthcare providers, including case 
definitions and information about signs and symptoms, is available at www.cdc.gov/zika/hc-
providers/index.html. All information and guidance, including those on Zika virus laboratory 
testing, may change as more data are gathered on this virus. Please check CDC’s Zika virus 
website regularly for the most current information (www.cdc.gov/zika/index.html). 
 
The U.S. Secretary of Health and Human Services (HHS) has declared that circumstances 
exist to justify the emergency use of in vitro diagnostic tests for the detection of Zika virus 
and/or diagnosis of Zika virus infection. This EUA will terminate when the HHS Secretary’s 
declaration terminates, unless FDA revokes it sooner. 
 
At this time, there are no FDA approved/cleared tests available that can detect Zika virus 
infection in clinical specimens in the US. Therefore, CDC has developed the Zika MAC-ELISA 
to detect evidence of Zika virus infection. 
 
When should the Zika MAC-ELISA test be performed? 
 
Anti-Zika IgM is typically detectable starting soon after onset of symptoms and is reliably 
detectable for approximately 12 weeks following infection.  If Zika virus infection is suspected 
based on CDC’s published clinical and/or epidemiological criteria, the Zika MAC-ELISA may 
be ordered and should be performed according to the CDC-issued guidance 
(http://cdc.gov/zika/laboratories/lab-guidance.html).  The algorithms included within the 
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guidance illustrate the appropriate Zika testing approach based on the presence of signs and 
symptoms, pregnancy status, and the time between onset of symptoms or suspected exposure 
and specimen collection.   
 
As disease manifestations of dengue and chikungunya virus infections can resemble those of 
Zika virus infection, additional testing for these viruses should be considered to aid in 
differentiating dengue and chikungunya virus infections from Zika virus infections. Please 
contact your state or local health department to facilitate testing.   
 
As of December 6, 2016, serum is the primary diagnostic specimen for Zika virus RNA and 
serologic testing, and should be the priority specimen for collection and Zika MAC-ELISA 
testing.  The Zika MAC-ELISA can also be used to test CSF when collected alongside a 
patient-matched serum.   
 
Specimens should be collected with appropriate infection control precautions and according to 
the manufacturer’s instructions for the specimen collection device, handling, and storage.  
Serum should be collected in serum separator tubes and centrifuged after collection to reduce 
the likelihood of hemolysis.    Additional guidance for collection of body fluid specimens for 
Zika diagnostic testing may be found at: http://www.cdc.gov/zika/laboratories/test-specimens-
bodyfluids.html. 
 
What does it mean if the specimen tests positive with the Zika MAC-ELISA?  
 
A positive test result from the Zika MAC-ELISA indicates that anti-Zika IgM antibodies were 
detected in the patient’s specimen.  Confirmation of Zika MAC-ELISA positive or equivocal 
results requires additional testing by CDC or by qualified laboratories designated by CDC and 
in consultation with CDC, using the CDC-issued algorithm published in the CDC laboratory 
guidance found at: http://cdc.gov/zika/laboratories/lab-guidance.html.   
 
Laboratory test results should always be considered in the context of clinical observations, 
epidemiological information, and travel history in making a final diagnosis and patient 
management decisions. For guidance on Zika virus, please refer to http://www.cdc.gov/zika/hc-
providers/index.html. 
 
Positive and equivocal Zika MAC-ELISA results are not definitive for diagnosis of Zika virus 
infection.  False positive results may occur in some patients with recent, closely-related 
flavivirus infections, such as dengue infections.  In patients who have received yellow fever or 
Japanese encephalitis vaccination, cross-reactive antibodies in both the IgM and neutralizing 
antibody assays may make it difficult to identify which flavivirus is causing the patient’s current 
illness.  It is possible that the Zika MAC-ELISA may generate positive results in patients with a 
history of non-Zika flavivirus infections.  In the event of a false positive result, risks to patients 
could include any or all of the following:  the impaired ability to detect and receive appropriate 
medical care for the true source of symptoms; in the case of pregnant women, an unnecessary 
increase in the monitoring of a woman’s pregnancy; or other unintended adverse effects. 
 
Due to cross-reactivity of anti-dengue IgM and IgG antibodies in tests to detect recent Zika 
virus infection, it may be difficult to determine the specific flavivirus causing the recent infection 
in patients with a history of flavivirus infection or in those who reside in areas where Zika 
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and/or dengue virus have been known to circulate. Due to this limitation, plaque reduction 
neutralization test (PRNT) is not currently routinely recommended for confirmation of Zika 
MAC-ELISA results in Puerto Rico. Please refer to CDC guidance, including the CDC 
laboratory guidance (http://www.cdc.gov/zika/laboratories/lab-guidance.html) for additional 
information about diagnostic testing recommendations in the United States and its territories.  
 
In the United States and its territories, Zika virus infection and disease (non-congenital and 
congenital) are nationally notifiable conditions and should be reported to the local or state 
health department. For guidance on Zika virus, please refer to http://www.cdc.gov/zika/hc-
providers/index.html.   
 
While there is an established association between Zika virus infection during pregnancy and 
microcephaly, detection of anti-Zika IgM antibodies in specimens collected from a pregnant 
woman does not provide definitive information about the health of her fetus and does not 
indicate imminent harm to her fetus. If a pregnant woman is diagnosed with Zika virus infection 
based on detection of anti-Zika IgM antibodies, issues such as timing of infection during the 
course of pregnancy, presence of symptoms and other factors may help determine the risk to 
her fetus.   
 
What does it mean if the specimen tests negative in the Zika MAC-ELISA?  
 
A negative Zika MAC-ELISA result does not rule out Zika virus infection, particularly if testing is 
conducted soon after onset of symptoms (before anti-Zika IgM antibodies levels are expected 
to become detectable) or more than 12 weeks after the infection is thought to have occurred 
(as anti-Zika IgM antibodies levels are expected to drop).  As with any test, providers must 
consider the patient’s likelihood of exposure and the possibility of false laboratory results when 
making treatment or other patient management decisions.   
 
Absence of laboratory evidence of Zika virus infection cannot definitively rule out Zika virus 
infection in persons with epidemiological risk factors.  All results should be considered in the 
context of clinical signs and symptoms, exposure risk and time since symptom onset, or in the 
absence of symptoms, time since exposure.  Conversely, a negative result in an asymptomatic 
patient with a lower likelihood of exposure (e.g., a short term traveler to an affected area) may 
suggest the patient is not infected.   
 
Guidance for healthcare providers, including those caring for pregnant women and women of 
reproductive age with possible Zika virus exposure, is available on the CDC 
website: http://www.cdc.gov/zika/hc-providers/index.html 
 
What has changed in this update to the Fact Sheet for Healthcare Providers? 
 
The main changes that have been made to the Fact Sheet for Healthcare Providers are the 
following: 
 
• Indications for testing and guidance for interpretation of a negative result have been 
updated to align with recently posted CDC Guidance for US Laboratories Testing for 
Zika Virus Infection (http://www.cdc.gov/zika/laboratories/lab-guidance.html). 
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• PRNT is not currently routinely recommended for confirmation of Zika MAC-ELISA 
results in Puerto Rico. 
 
Reporting Adverse Events  
 
You should report adverse events, including problems with test performance or results, to 
MedWatch at www.fda.gov/medwatch, by submitting a MedWatch Form 3500 (available 
at http://www.fda.gov/medwatch/safety/FDA-3500_fillable.pdf) or by calling 1-800-FDA-1088.  
 
All patients should receive the Fact Sheet for Patients: Understanding Results from the 
Zika MAC-ELISA. 
 
Contact Information for the Manufacturer: 
CDC Emergency Operations Center (EOC) 
1600 Clifton Road 
Atlanta, Georgia, USA, 30329 
Office phone: CDC EOC (770-488-7100)  
 
Any significant new findings that negatively impact the performance of the test and that are 
observed during the course of the emergency use of the Zika-MAC ELISA will be made 
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